SynthesisBMC endocrine disorders2026
Efficacy and safety of tocilizumab in the treatment of Graves' orbitopathy: a systematic review and meta-analysis.
Synthesis in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeThis meta-analysis aimed to explore the safety and efficacy of tocilizumab (TCZ) for moderate to severe steroid-resistant active Graves' orbitopathy (GO).
designSystematic review and meta-analysis of 1 randomized controlled trial and 6 cohort studies. MATERIALS AND
methodsWe searched Pubmed, EMBASE and The Cochrane Library for relevant studies published before June 1, 2022. The primary outcome indicator was the change in clinical activity score (CAS). Secondary outcome indicators were a reduction in proptosis and correction of diplopia. Random effects models were used for all analytical models. The mean difference (MD) and standardized mean difference (SMD) of the combined effect sizes of these outcome indicators were calculated for continuous variables. The odds ratio (OR) of the combined effect size of these outcome indicators was calculated for the dichotomous variables. The study was registered with PROSPERO, CRD 42,022,381,596.
resultSeven studies (n = 161) were included in the meta-analysis. The analysis showed that treatment of moderate to severe steroid-resistant active GO patients with TCZ resulted in improvements in CAS [SMD 4.25, 95% CI(2.94, 5.57), P < 0.00001], proptosis [MD 2.13, 95% CI (1.45, 2.80), P < 0.00001] and diplopia [OR 6.00, 95% CI(2.93, 12.30), P < 0.00001].
conclusionOur results strongly suggest that the use of TCZ for the treatment of patients with moderate to severe GO is very beneficial in reducing CAS, improving proptosis, and correcting diplopia. However, the incidence of serious adverse events varied among the included studies. Future randomized controlled trials (RCT) are necessary for further exploration. CLINICAL TRIAL NUMBER: Not applicable. PROSPERO: CRD42022381596.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.